Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.

This article reviews the current understanding, clinical features, diagnostic tests, and treatment options for androgenetic alopecia and reports no new clinical results.

In this study, bicalutamide showed promise in managing female pattern hair loss and reducing minoxidil-induced hypertrichosis, though further research is necessary to refine its use and establish its role in treatment.

This article discusses therapeutic options for managing androgenic alopecia but reports no new clinical results, recommending selective and safe drugs such as growth stimulators and DHT inhibitors.

Minoxidil helps hair growth by improving blood vessel function.

This study developed a bifunctional sodium hyaluronate microneedle patch incorporating glycyrrhizin-loaded dutasteride micelles and mesoporous polydopamine nanoparticles, which effectively inhibited DHT and reduced ROS in hair follicle cells, resulting in significantly accelerated hair growth in vitro and in vivo.

This study identified altered neurological pathways and potential drug targets involved in androgenetic alopecia, suggesting areas for future research and possible therapies.

This study concluded that S. hexaphylla extract may improve androgenetic alopecia by reducing 5α-reductase and androgen receptor levels, inhibiting apoptosis, and promoting keratinocyte proliferation in experimental models.

This review discusses the molecular mechanisms of androgens and androgen receptors in skin disorders, particularly androgenetic alopecia, and reports no new clinical results; it highlights potential areas for future treatment development.

This article discusses the FDA approval of dutasteride for benign prostatic hypertrophy and explores its potential role in treating androgenetic alopecia but reports no new clinical findings.

This review concludes that finasteride and dutasteride are the most evidence-supported oral treatments for androgenetic alopecia, with dutasteride offering slightly greater hair count improvements and both affected by genetic response modifiers.

This review concluded that while topical prostaglandin analogues show some potential in treating androgenetic alopecia, evidence is still limited and no products have regulatory approval.

This review paper provides a comprehensive overview of Dutasteride, detailing its pharmacological properties, mechanisms, and therapeutic applications, particularly for androgenetic alopecia and benign prostatic hyperplasia, and discusses its potential use in prostate cancer prevention and transgender medicine.

This study found that the new delivery system HL@Mi enhanced the skin penetration, local bioavailability, and safety of minoxidil, supporting improved hair growth in an androgenetic alopecia animal model.

This study found that dutasteride 0.5 mg was generally well-tolerated and led to overall improvement in male patients aged 18 to 41 with androgenic alopecia in a Korean clinical practice setting.

This study observed that dutasteride treatment led to improvement in acne vulgaris among two male patients with androgenetic alopecia, suggesting its potential as a treatment option for concurrent conditions.

This study found that a microneedle system delivering VEGF and Ritlecitinib improved hair regeneration in mice with androgenetic alopecia, showing faster anagen onset and better hair quality compared to minoxidil.

This study reviews the effectiveness and safety of finasteride and dutasteride for treating androgenetic alopecia, highlighting that dutasteride reduces DHT more deeply than finasteride, with genetic factors influencing patient response and both drugs being evidence-supported options for men and women.

This study developed a topical dutasteride-loaded Insitu-emulgel for treating androgenetic alopecia, finding it effectively controls drug release, enhances skin penetration, and may improve patient compliance compared to traditional topical treatments, though further clinical research is underway.

This review discusses spironolactone as an effective and potentially safer treatment for androgenic alopecia, particularly when used with minoxidil, but calls for more high-quality clinical trials.

This study found that dihydrotestosterone induced hair loss and changes in hair morphology in male C57BL/6 mice, effects that could be partially reversed by the AR antagonist bicalutamide.

This invention reports piperazine derivatives as potent inhibitors of type 3 17β-hydroxysteroid dehydrogenase, suggesting potential therapeutic applications in treating prostate cancer, acne, and androgenic alopecia.

This article discusses the role of dihydrotestosterone in human prostatic adenocarcinoma growth and suggests that 6-methyleneprogesterone could be used to inhibit DHT for treating hormone-responsive prostate cancer, without new clinical findings.

The researchers reported that nano-cerium oxide improved androgenetic alopecia in mice by increasing the ratio of terminal to vellus hairs, elevating IGF-1 expression, and reducing TGF-β and DHT levels in the skin, suggesting potential for drug development.

This study found that finasteride-loaded microspheres effectively treated androgenic alopecia in a mouse model, showing similar hair growth effects to orally-administered finasteride.

In this study, researchers found that the thyroxine receptor agonist TDM10842 accelerated the onset of anagen, a hair growth phase, in C3H mice, potentially through activation of the Wnt/beta-catenin and Hedgehog pathways, with Pclaf playing a key role in this process.

This review discusses the efficacy and safety of 5-alpha reductase inhibitors for treating androgenetic alopecia, noting concerns about sexual side effects, which are typically uncommon and often resolve over time.

This study demonstrated that ellagic acid promoted hair regrowth in a DHT-induced androgenic alopecia mouse model by inhibiting ferroptosis through the activation of the Wnt/β-catenin signaling pathway, suggesting its potential as a treatment for androgenic alopecia.